<DOC>
	<DOCNO>NCT00000814</DOCNO>
	<brief_summary>To compare antiviral activity , safety , toxicity , steady-state pharmacokinetics zidovudine , didanosine , nevirapine use combination patient HIV infection . The duration clinical benefit zidovudine ( AZT ) may limit development viral resistance drug . Use combination antiretroviral therapy potentially reduce viral load prevent emergence multidrug resistance .</brief_summary>
	<brief_title>A Comparative Study Combination Antiretroviral Therapy Children Adolescents With Advanced HIV Disease</brief_title>
	<detailed_description>The duration clinical benefit zidovudine ( AZT ) may limit development viral resistance drug . Use combination antiretroviral therapy potentially reduce viral load prevent emergence multidrug resistance . In Stage 1 study , minimum 22 patient randomize three treatment arm : didanosine ( ddI ) plus AZT plus nevirapine ( NVP ) ; ddI plus AZT ; ddI plus NVP . After 12 week treatment , study proceeds Stage 2 provide least 40 percent patient Stage 1 show reduction least 40 percent baseline ICD p24 antigen great equal 70 pg/ml AND few two patient experience grade 4 rash . Patients Stage 1 continue treatment additional 36 week . In Stage 2 , additional patient randomize original treatment regimen maximum 130 patient per arm enter . Stage 2 patient receive treatment least 48 week . AS PER AMENDMENT 02/12/97 : As 2/28/97 , patient receive study drug offer blind study drug additional 16 week ( 6/30/97 ) . Patients unblinded 5/23/97 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Erythropoietin . Concurrent Treatment : Allowed : Transfusion . Patients must : Progressive HIV disease . At least 24 week prior cumulative nucleoside analog antiretroviral monotherapy combination therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active malignancy require chemotherapy . Currently receive therapy ACTG primary therapy salvage protocol NOT meet endpoint study . Known intolerance ( hematologic ) toxicity ddI , AZT , NVP dose use study . Concurrent Medication : Excluded ( unless exemption make study chair ) : Oral anticoagulant ( warfarin , dicumarol ) . Oral contraceptive . Digitalis glycoside . Phenytoin . Theophylline . Patients follow prior condition exclude : History clinical pancreatitis . History grade 2 bad peripheral neuropathy . Prior Treatment : Excluded : Acute treatment serious bacterial , viral , opportunistic infection within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>